AR037138A1 - Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion - Google Patents

Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion

Info

Publication number
AR037138A1
AR037138A1 ARP020102523A ARP020102523A AR037138A1 AR 037138 A1 AR037138 A1 AR 037138A1 AR P020102523 A ARP020102523 A AR P020102523A AR P020102523 A ARP020102523 A AR P020102523A AR 037138 A1 AR037138 A1 AR 037138A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
formulation
weight
fulvestrant
vehicle
Prior art date
Application number
ARP020102523A
Other languages
English (en)
Spanish (es)
Inventor
Julie Cahill
Paul Gellert
Alan Irving
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR037138A1 publication Critical patent/AR037138A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ARP020102523A 2001-07-07 2002-07-05 Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion AR037138A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30

Publications (1)

Publication Number Publication Date
AR037138A1 true AR037138A1 (es) 2004-10-27

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102523A AR037138A1 (es) 2001-07-07 2002-07-05 Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion

Country Status (15)

Country Link
EP (1) EP1406662A1 (ru)
JP (1) JP2004534093A (ru)
CN (1) CN1553815A (ru)
AR (1) AR037138A1 (ru)
BR (1) BR0210898A (ru)
CA (1) CA2453111A1 (ru)
CO (1) CO5560585A2 (ru)
HU (1) HUP0400115A3 (ru)
IL (1) IL159576A0 (ru)
IS (1) IS7097A (ru)
MX (1) MXPA04000028A (ru)
NO (1) NO20040047L (ru)
PL (1) PL367624A1 (ru)
RU (1) RU2004102393A (ru)
WO (1) WO2003006064A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600065B (zh) * 2012-03-31 2014-08-13 莱普德制药有限公司 一种氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
AU2017261321B2 (en) * 2016-05-06 2023-03-09 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2017208847A1 (ja) 2016-05-31 2017-12-07 富士フイルム株式会社 医薬組成物
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
EP3747442B1 (en) * 2018-01-31 2024-07-10 FUJIFILM Corporation Method for producing preparation for injection
CN111481559B (zh) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 一种高浓度的氟维司群组合物及其制备方法
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
CA2453111A1 (en) 2003-01-23
NO20040047L (no) 2004-02-23
JP2004534093A (ja) 2004-11-11
MXPA04000028A (es) 2004-05-21
HUP0400115A2 (hu) 2004-06-28
IS7097A (is) 2004-01-05
EP1406662A1 (en) 2004-04-14
PL367624A1 (en) 2005-03-07
CO5560585A2 (es) 2005-09-30
IL159576A0 (en) 2004-06-01
HUP0400115A3 (en) 2005-11-28
BR0210898A (pt) 2004-06-22
WO2003006064A1 (en) 2003-01-23
CN1553815A (zh) 2004-12-08
RU2004102393A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
AR037138A1 (es) Formulacion farmaceutica, uso de fulvestrant en la preparacion de la misma y jeringa o vial esteriles que comprenden dicha formulacion
JP5670335B2 (ja) ベンダムスチン液体製剤
ES2186517B2 (es) Formulacion farmaceutica que contiene fulvestrant.
CN1112924C (zh) 用于静脉注射的雷怕霉素制剂
ES2261570T3 (es) Medicamento basado en gestagenos para aplicacion por via dermica que contiene acido ascorbico asi como sales del mismo.
JP2003519659A5 (ru)
US20170319702A1 (en) Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent
JP3950993B2 (ja) タキサン系の誘導体に基づく製薬組成物
AR098109A2 (es) Un análogo de epotilona, su uso para la preparación de un medicamento y una composición farmacéutica adecuada para administración parenteral
US8420130B1 (en) Pharmaceutical formulation of a didemnin compound
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
UY24281A1 (es) Procedimiento para preparar composiciones estables de vacunas para la administracion parenteral
US10314880B2 (en) Composition comprising bortezomib
RU2006105645A (ru) Лиофилизированные композиции cci-779
KR20150074167A (ko) Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
US8263567B2 (en) Treatment of hyperproliferative conditions of body surfaces
AU2002320964A1 (en) Treatment of hyperproliferative conditions of body surfaces
KR20010006361A (ko) 경점막 투여 제제
MXPA00008124A (en) Pharmaceutical formulation of a didemnin compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal